Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Tomasz M. Beer(Exact Sciences (United States)), Bertrand Tombal(Cliniques Universitaires Saint-Luc), Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center), Cora N. Sternberg(Cornell University), Karim Fizazi(Université de Lille), Suman Bhattacharya(University of Limerick), Mary‐Ellen Taplin(University of Massachusetts Chan Medical School), Choung‐Soo Kim(Asan Medical Center), Yohann Loriot(Institut Gustave Roussy), Peter Iversen(University of Copenhagen), Andrew J. Armstrong(Duke University), Paul N. Mainwaring(Australasia Paediatric Endocrine Group), Go Kimura(Nippon Medical School), Fred Saad(Centre Hospitalier de l’Université de Montréal), Ian D. Davis(Austin Health), Sarah B. Noonberg, Johann S. de Bono(Royal Marsden NHS Foundation Trust), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Anthony M. Joshua(St Vincent's Hospital Sydney), Christopher P. Evans(University of Nevada, Reno), Peter Venner(Cancer Institute (WIA)), Harry H. Mansbach, De Phung(Astellas Pharma (United States)), Kurt Miller(Charité - Universitätsmedizin Berlin), Simon Chowdhury(Sarah Cannon Research Institute), Celestia S. Higano(University of British Columbia), Frank Perabo(Astellas Pharma (United States)), Joan Carles(Vall d'Hebron Hospital Universitari)
Cited by 3,029
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k